Users can get a trial run of the neuromodulation therapy before having the Proclaim DRG system implanted.
Abbott Laboratories has nabbed approvals for a chronic pain treatment device that patients can try before getting an implanted version of the technology. The Dorsal Root Ganglion (DRG) Invisible Trial System now has CE mark and a nod from FDA. The Abbott Park, IL-based company said patients who find adequate pain relief with DRG therapy can then have the Proclaim DRG System implanted.
The Proclaim DRG includes an implantable neuromodulator that stimulates the dorsal root ganglion (DRG), an Apple iPad for programming the device, and an iPod touch for the patient control of the device.
“Abbott’s DRG Invisible Trial System is very much focused on the person who is seeking pain relief,” Allen Burton, M.D., medical director of neuromodulation, at Abbott told MD+DI. “This evaluation period can give insight into whether the technology will provide meaningful relief to people who have oftentimes tried many failed therapies previously. This unique ability to “test drive” the procedure before committing to fully implanted therapy is an important part of our patient-centric DRG therapy.”